Clinical Trial Search

Primary: Maximum (Peak) Plasma Concentration of the Drug [Cmax] and Minimum (Trough) Plasma Concentration of the Drug [Cmin] After Tolvaptan Treatment on Day 7. — 140; 175; 350…

Primary: Efficacy Primary Endpoint - Percentage of Patients Responding to Treatment — 0; 11; 10 Participants

Primary: Hydromorphone Use/24 Hours postOP in mg/kg — .13; .09; .27; .19 mg/kg

Primary: Number of Participants Experiencing Treatment-emergent Adverse Events Considered Related to Florbetapir Administration — 21; 6; 5; 5 Participants

Primary: Number of Participants Reporting Adverse Events (AEs) — 28; 5; 29; 11 Participants

Primary: Number of Subjects With Major Bleeding and Clinically Relevant Non-Major Bleeding Events — 0; 0; 0; 0 Participants

Primary: Complete Response (CR) Rate — 98; 4; 9; 7 Participants

Primary: Number of Participants With Composite of Symptomatic Ischemic Stroke by Day 28 and Unrecognized Brain Infarction Assessed by MRI at Day 28

Primary: Percentage of Participants With a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24 — 33.3; 61.7 Percentage of participants…

Primary: Number of Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Positive Clusters — 0.251560; 0.269518 VEGFR1+ clusters per hpf — p=0.345

Primary: Change of HbA1c Level From Baseline — -0.21; -0.17; -0.43; -0.04 (%)

Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848

Primary: Over All Survival — 15.9 months

Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants

Primary: Number of Participants With Clearing of Corneal Fluorescein Staining at Week 5 at Week 5 — 5; 7; 12 Participants